title: Sunitinib in kidney cancer: 10 years of experience and development.
abstract: Sunitinib is a multi-target, anti-angiogenic tyrosine kinase inhibitor and a key molecule in the treatment of metastatic renal cell carcinoma (mRCC). Since it first demonstrated its efficacy ten years ago, overall survival of mRCC has more than doubled, in part due to sunitinib. In most recent years, progress has been made in the comprehension of its mechanism of action and resistance. Areas Covered: In this article, clinical trials involving sunitinib in kidney cancer have been reviewed, defining its different indications in metastatic and localized RCC. The rationale of sunitinib's efficacy, preclinical trials, past-clinical trials and ongoing clinical trials are summarized. Dose and scheme base are discussed, as the recommended dosage is frequently not well tolerated. Combination therapies appear to be toxic. Novel immunotherapies are changing the landscape of mRCC treatment and challenging sunitinib. Special attention has been paid towards cancer cell biology and immunity involved in treatment response. Expert Commentary: Sunitinib's place in the therapeutic arsenal is being redefined with the arrival of major challengers. Dosage and scheduling of sunitinib remains a major challenge.
authors.affiliation: a Oncology Department , Georges Pompidou European Hospital , Paris , France.
authors.forename: Elise
authors.initials: E
authors.lastname: Nassif
authors.affiliation: a Oncology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Constance
authors.initials: C
authors.lastname: Thibault
authors.affiliation: a Oncology Department , Georges Pompidou European Hospital , Paris , France.|b Cordeliers Research Center, UMRS1138 Team 13 Cancer, Immune Control and Escape , Paris , France ​​.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Yann
authors.initials: Y
authors.lastname: Vano
authors.affiliation: c Radiology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Laure
authors.initials: L
authors.lastname: Fournier
authors.affiliation: d Biological Hematology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Mauge
authors.affiliation: d Biological Hematology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Verkarre
authors.affiliation: e Urology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Marc-Olivier
authors.initials: MO
authors.lastname: Timsit
authors.affiliation: e Urology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Mejean
authors.affiliation: f Immunology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Eric
authors.initials: E
authors.lastname: Tartour
authors.affiliation: a Oncology Department , Georges Pompidou European Hospital , Paris , France.|g Université Paris Descartes Sorbonne Paris-Cité , Paris 5 , France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000077210:Sunitinib; D015996:Survival Rate
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib
keywords: Kidney cancer; anti-angiogenic therapy; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor